Jonathan Chou

10.2k total citations · 2 hit papers
67 papers, 6.0k citations indexed

About

Jonathan Chou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jonathan Chou has authored 67 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 21 papers in Surgery. Recurrent topics in Jonathan Chou's work include Bladder and Urothelial Cancer Treatments (20 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Prostate Cancer Treatment and Research (15 papers). Jonathan Chou is often cited by papers focused on Bladder and Urothelial Cancer Treatments (20 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Prostate Cancer Treatment and Research (15 papers). Jonathan Chou collaborates with scholars based in United States, Canada and Taiwan. Jonathan Chou's co-authors include Zena Werb, Caroline Bonnans, Sylvain Provot, Felix Y. Feng, Antonello Bonci, M. Scott Bowers, Billy T. Chen, Audrey Brenot, Jeffrey Lin and Jung‐whan Kim and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Jonathan Chou

59 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Remodelling the extracellular matrix in development and disease

2014 3.1k citations Jonathan Chou, Zena Werb et al. profile →
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

2018 384 citations Yi-Mi Wu, Marcin Cieślik et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Chou United States	22	2.4k	1.6k	1.2k	1.0k	838	67	6.0k
Richard Grose United Kingdom	35	4.7k 2.0×	1.3k 0.8×	1.1k 0.9×	630 0.6×	1.5k 1.8×	77	9.4k
Yi Tang China	41	3.2k 1.3×	1.3k 0.8×	670 0.6×	427 0.4×	407 0.5×	132	5.7k
Ming‐Jer Tang Taiwan	50	3.4k 1.4×	1.0k 0.7×	638 0.5×	464 0.5×	1.9k 2.2×	173	6.8k
Petra Knaus Germany	50	4.6k 1.9×	749 0.5×	584 0.5×	876 0.9×	1.1k 1.4×	132	7.4k
Wei‐Qiang Gao China	54	4.9k 2.0×	1.6k 1.0×	1.7k 1.4×	1.5k 1.5×	594 0.7×	235	9.3k
Rona S. Carroll United States	52	3.2k 1.4×	1.2k 0.8×	759 0.6×	390 0.4×	285 0.3×	150	7.6k
Kurt S. Zänker Germany	40	2.1k 0.9×	2.2k 1.4×	995 0.8×	514 0.5×	1.2k 1.4×	148	6.1k
Johan Kreuger Sweden	28	4.1k 1.7×	931 0.6×	920 0.8×	361 0.4×	2.0k 2.3×	57	6.3k
Sidharth V. Puram United States	32	2.1k 0.9×	1.7k 1.1×	1.0k 0.9×	546 0.5×	319 0.4×	159	4.9k
Michael D. Henry United States	41	5.5k 2.3×	1.0k 0.7×	1.2k 1.0×	586 0.6×	1.5k 1.8×	105	8.4k

Countries citing papers authored by Jonathan Chou

Since Specialization

Citations

This map shows the geographic impact of Jonathan Chou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Chou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Chou more than expected).

Fields of papers citing papers by Jonathan Chou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Chou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Chou. The network helps show where Jonathan Chou may publish in the future.

Co-authorship network of co-authors of Jonathan Chou

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Chou. A scholar is included among the top collaborators of Jonathan Chou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Chou. Jonathan Chou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kouchkovsky, Ivan de, Li Zhang, Xiaolin Zhu, et al.. (2025). Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy.. Journal of Clinical Oncology. 43(5_suppl). 46–46.

Kwon, Daniel H., Hala T. Borno, Rohit Bose, et al.. (2024). Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer Medicine. 13(22). e70433–e70433.

Bobba, Kondapa Naidu, Anil P. Bidkar, Niranjan Meher, et al.. (2024). Development of CD46 targeted alpha theranostics in prostate cancer using ¹³⁴Ce/²²⁵Ac-Macropa-PEG₄-YS5. Theranostics. 14(4). 1344–1360. 13 indexed citations

Badura, Michelle L., Patrick C. O’Leary, Troy M. Robinson, et al.. (2024). Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nature Cancer. 5(12). 1885–1901. 4 indexed citations

Chou, Jonathan, et al.. (2023). Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series. Clinical Genitourinary Cancer. 22(2). 315–321. 1 indexed citations

Carretero-González, Alberto, Jun Zhu, Emily A. Egusa, et al.. (2023). Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Clinical Cancer Research. 29(7). 1232–1242. 6 indexed citations

Zhu, Xiaolin, Li Zhang, Kevin Reyes, et al.. (2023). Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).. Journal of Clinical Oncology. 41(6_suppl). 534–534. 2 indexed citations

O’Leary, Patrick C., Huadong Chen, Benjamin J. Polacco, et al.. (2022). Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer Research. 82(21). 3950–3961. 17 indexed citations

Chou, Jonathan, Martin Sjöström, Emily A. Egusa, et al.. (2022). TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. European Urology Oncology. 5(6). 714–718. 56 indexed citations

10.

Chu, Carissa, Martin Sjöström, Emily A. Egusa, et al.. (2021). Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clinical Cancer Research. 27(18). 5123–5130. 101 indexed citations

11.

Chou, Jonathan, David A. Quigley, Troy M. Robinson, Felix Y. Feng, & Alan Ashworth. (2020). Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discovery. 10(3). 351–370. 214 indexed citations

12.

Zhang, Li, Patrick Devine, Bradley A. Stohr, et al.. (2020). 769P APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma. Annals of Oncology. 31. S593–S593. 1 indexed citations

13.

Owyong, Mark, Jonathan Chou, Renske J.E. van den Bijgaart, et al.. (2019). MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Science Alliance. 2(6). e201800226–e201800226. 78 indexed citations

14.

Wu, Yi-Mi, Marcin Cieślik, Robert J. Lonigro, et al.. (2018). Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell. 173(7). 1770–1782.e14. 384 indexed citations breakdown →

15.

Shahi, Payam, et al.. (2014). The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion. Journal of Biological Chemistry. 290(6). 3803–3813. 27 indexed citations

16.

Littlepage, Laurie E., Adam S. Adler, Hosein Kouros‐Mehr, et al.. (2012). The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression. Cancer Discovery. 2(7). 638–651. 54 indexed citations

17.

Chou, Jonathan. (2012). Insights into breast cancer metastasis: understanding the roles of transcription factors, microRNAs and the tumor microenvironment. eScholarship (California Digital Library). 1 indexed citations

18.

Slorach, Euan M., Jonathan Chou, & Zena Werb. (2011). Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes & Development. 25(5). 471–484. 72 indexed citations

19.

Borgland, Stephanie L., M. Scott Bowers, Jennifer L. Thompson, et al.. (2009). Orexin A/Hypocretin-1 Selectively Promotes Motivation for Positive Reinforcers. Journal of Neuroscience. 29(36). 11215–11225. 281 indexed citations

20.

Chou, Jonathan, Sylvain Provot, & Zena Werb. (2009). GATA3 in development and cancer differentiation: Cells GATA have it!. Journal of Cellular Physiology. 222(1). 42–49. 233 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact